Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 507
- Registration Number
- NCT03525574
- Locations
- 🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸New York Medical College, Valhalla, New York, United States
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT03486236
- Locations
- 🇬🇧
The Medicines Evaluation Unit, Manchester, United Kingdom
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 116
- Registration Number
- NCT03460990
- Locations
- 🇺🇸
Yale New Haven Medical Center, New Haven, Connecticut, United States
🇺🇸St. Luke's CF Center of Idaho, Boise, Idaho, United States
🇺🇸Helen DeVos Children's Hospital CF Center, Grand Rapids, Michigan, United States
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 385
- Registration Number
- NCT03447249
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇦🇺Institute for Respiratory Health Inc./ Sir Charles Gairdner Hospital, Nedlands, Australia
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 484
- Registration Number
- NCT03447262
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Drexel University College of Medicine / Drexel Adult Cystic Fibrosis Center, Philadelphia, Pennsylvania, United States
🇮🇪Cork University Hospital, Cork, Ireland
A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 89
- Registration Number
- NCT03304522
- Locations
- 🇺🇸
Duke Neurological Disorders Clinic, Durham, North Carolina, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Xenoscience Inc. - 21st Century Neurology, Phoenix, Arizona, United States
Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis
- Conditions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT03278314
A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 86
- Registration Number
- NCT03277196
- Locations
- 🇺🇸
Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 225
- Registration Number
- NCT03227471
- Locations
- 🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Mater Adult Hospital, Brisbane, Australia
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 124
- Registration Number
- NCT03224351
- Locations
- 🇺🇸
Rutgers-Robert Wood Johnson Medical School/ Rutgers-Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick, New Jersey, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States